Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma.
Burkitt-like lymphoma
MYC
apoptic index
caspase - 3
dog
prognosis
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
12
2020
accepted:
24
02
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
In dogs, Burkitt-like lymphoma (B-LL) is rare tumor and it is classified as a high-grade B-cell malignancy. The diagnosis is challenging because of the similar histologic appearance with other histotypes, no defined phenotypical criteria and poorly described clinical aspects. The aim of the study was to provide a detailed description of clinical and morphological features, as well as immunophenotypical profile of B-LL in comparison with the human counterpart. Thirteen dogs with histologically proven B-LL, for which a complete staging and follow-up were available, were retrospectively selected. Immunohistochemical expression of CD20, PAX5, CD3, CD10, BCL2, BCL6, MYC, and caspase-3 was evaluated. Histologically, all B-LLs showed a diffuse architecture with medium to large-sized cells, high mitotic rate and diffuse starry sky appearance. B-phenotype of neoplastic cells was confirmed both by flow-cytometry and immunohistochemistry. Conversely, B-LLs were negative for BCL2 and MYC, whereas some cases co-expressed BCL6 and CD10, suggesting a germinal center B-cell origin. Disease stage was advanced in the majority of cases. All dogs received CHOP-based chemotherapy with or without immunotherapy. Despite treatment, prognosis was poor, with a median time to progression and survival of 130 and 228 days, respectively. Nevertheless, ~30% of dogs survived more than 1 year. An increased apoptotic index, a high turnover index and caspase-3 index correlated with shorter survival. In conclusion, canine B-LL shows phenotypical differences with the human counterpart along with features that might help to differentiate this entity from diffuse large B-cell lymphoma.
Identifiants
pubmed: 33816589
doi: 10.3389/fvets.2021.647009
pmc: PMC8010238
doi:
Types de publication
Journal Article
Langues
eng
Pagination
647009Informations de copyright
Copyright © 2021 Aresu, Agnoli, Nicoletti, Fanelli, Martini, Bertoni and Marconato.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Vet Diagn Invest. 2008 Jul;20(4):393-413
pubmed: 18599844
Blood Cancer J. 2019 Nov 20;9(12):91
pubmed: 31748534
Postgrad Med J. 2008 Jul;84(993):372-7
pubmed: 18716017
Blood. 2001 Jun 15;97(12):3713-20
pubmed: 11389007
J Exp Med. 2007 Nov 26;204(12):2989-3001
pubmed: 17998390
Genes Chromosomes Cancer. 1994 Oct;11(2):85-90
pubmed: 7529553
Int J Cancer. 2008 Dec 1;123(11):2658-63
pubmed: 18767045
Vet Pathol. 2011 Jan;48(1):198-211
pubmed: 20861499
Vet Comp Oncol. 2015 Dec;13(4):494-7
pubmed: 26463403
Vet Pathol. 2002 Jan;39(1):42-55
pubmed: 12102218
Vet Comp Oncol. 2015 Dec;13(4):475-80
pubmed: 24341365
Vet Comp Oncol. 2017 Dec;15(4):1269-1279
pubmed: 27514648
J Int Oral Health. 2015 Jan;7(1):40-3
pubmed: 25709366
J Clin Oncol. 1986 Jun;4(6):847-58
pubmed: 3711961
Genes (Basel). 2017 Mar 30;8(4):
pubmed: 28358317
Vet J. 2019 Apr;246:78-84
pubmed: 30902194
Cancer Discov. 2018 Feb;8(2):150-163
pubmed: 29358508
Blood. 2014 Feb 20;123(8):1187-98
pubmed: 24398325
Vet J. 2004 Mar;167(2):158-66
pubmed: 14975390
Indian J Cancer. 2013 Jul-Sep;50(3):274-83
pubmed: 24061471
Vet Microbiol. 2011 May 12;150(1-2):15-20
pubmed: 21242039
Vet Comp Oncol. 2020 Dec;18(4):645-655
pubmed: 32154977
Vet Pathol. 2013 Sep;50(5):738-48
pubmed: 23444036
Cytometry B Clin Cytom. 2016 Nov;90(6):525-530
pubmed: 26663674
J Clin Oncol. 2008 Nov 1;26(31):5107-12
pubmed: 18768434
J Vet Diagn Invest. 2000 Mar;12(2):111-7
pubmed: 10730938
J Clin Oncol. 2000 Nov 1;18(21):3707-21
pubmed: 11054444
J Immunother Cancer. 2019 Jun 7;7(1):146
pubmed: 31174615
Hematology Am Soc Hematol Educ Program. 2009;:523-31
pubmed: 20008237
Blood Rev. 2006 Nov;20(6):319-32
pubmed: 16884838
BMC Cancer. 2015 Oct 09;15:668
pubmed: 26453442
J Biol Chem. 2018 Nov 30;293(48):18757-18769
pubmed: 30404920
Vet Comp Oncol. 2015 Dec;13(4):348-62
pubmed: 23782432
Vet Comp Oncol. 2010 Mar;8(1):28-37
pubmed: 20230579
Am J Surg Pathol. 2005 Aug;29(8):1086-94
pubmed: 16006805
Acta Haematol. 2015;133(2):221-5
pubmed: 25376208
Haematologica. 2019 Jun;104(6):e256-e259
pubmed: 30545928
Am J Pathol. 1997 Jan;150(1):155-65
pubmed: 9006332
Am J Hematol. 2012 Jun;87(6):573-8
pubmed: 22488262
Vet Pathol. 2010 May;47(3):414-33
pubmed: 20472804
J Clin Oncol. 1983 Nov;1(11):677-81
pubmed: 6689423
Mol Cytogenet. 2019 Feb 1;12:3
pubmed: 30733831
Clin Cancer Res. 2014 Feb 1;20(3):668-77
pubmed: 24300788
Vet Comp Oncol. 2018 Jun;16(2):246-252
pubmed: 29205839
Vet Pathol. 2016 Jan;53(1):7-9
pubmed: 26712813
Blood. 2008 Jun 15;111(12):5683-90
pubmed: 18391076